| Effects of baseline level of triglycerides on changes in lipid levels from combined fluvastatin + fibrate (bezafibrate, fenofibrate, or gemfibrozil). | |
| | |
MedLine Citation:
|
PMID: 14516878 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
This analysis was conducted to evaluate the effect of baseline triglyceride levels on lipid and lipoprotein changes after treatment with the combination of fluvastatin and fibrates. The analysis involved pooling data from 10 studies that included 1,018 patients with either mixed hyperlipidemia or primary hypercholesterolemia. Patients received a combination of fluvastatin and a fibrate (bezafibrate, fenofibrate, or gemfibrozil) from 16 to 108 weeks. The combination of fluvastatin and a fibrate improved lipid profiles, with reductions in triglycerides, low-density lipoprotein (LDL) cholesterol, and non-high-density lipoprotein (non-HDL) cholesterol that were dependent on baseline triglyceride levels. The greatest triglyceride reductions were observed in patients with high baseline triglyceride levels (> or =400 mg/dl) (41%, p <0.0001). The greatest LDL cholesterol and non-HDL cholesterol reductions occurred in patients with normal baseline triglyceride levels (<150 mg/dl) (35% and 33%, respectively; p <0.0001). The combined fluvastatin-fibrate therapy was well tolerated. Two patients (0.2%) (1 patient on fluvastatin 80 mg + gemfibrozil 1,200 mg and 1 patient on fluvastatin 20 mg + fenofibrate 200 mg) had creatine kinase levels > or =10 times the upper limit of normal, 11 patients (1.1%) had an elevation in alanine transaminase >3 times the upper limit of normal, and 7 patients (0.7%) had elevations in aspartate transaminase >3 times the upper limit of normal. Combined fluvastatin-fibrate therapy takes advantage of the complementary effects of the 2 agents, with the extent of triglyceride, LDL cholesterol, and non-HDL cholesterol lowering dependent on baseline triglyceride levels. The combination of fluvastatin and fibrates was well tolerated with no major safety concerns. |
| | |
Authors:
|
Michel Farnier; Thomas Salko; Jonathan L Isaacsohn; August J Troendle; Sylvie Dejager; Leonard Gonasun |
Related Documents
:
|
8130968 - Plasma lipid, lipoprotein and apolipoprotein profiles in nigerian university athletes a... 6594148 - Serum lipid and lipoprotein-cholesterol values in cord blood and on the sixth postnatal... 9865668 - Testosterone, sex hormone-binding globulin, lipoproteins, and vascular disease risk. 8891888 - Effect of a reduced-fat diet with or without pravastatin on glucose tolerance and insul... 22831978 - (1)h nmr-based metabolite profiling of diet-induced obesity in a mouse mode. 1765328 - Effects of high levels of brussels sprouts in the diet of rats. |
Publication Detail:
|
Type: Comparative Study; Journal Article; Research Support, Non-U.S. Gov't |
Journal Detail:
|
Title: The American journal of cardiology Volume: 92 ISSN: 0002-9149 ISO Abbreviation: Am. J. Cardiol. Publication Date: 2003 Oct |
Date Detail:
|
Created Date: 2003-09-30 Completed Date: 2003-10-28 Revised Date: 2006-11-15 |
Medline Journal Info:
|
Nlm Unique ID: 0207277 Medline TA: Am J Cardiol Country: United States |
Other Details:
|
Languages: eng Pagination: 794-7 Citation Subset: AIM; IM |
Affiliation:
|
Point Médical, Dijon, France. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Age Factors Antilipemic Agents / administration & dosage Bezafibrate / administration & dosage* Drug Combinations Fatty Acids, Monounsaturated / administration & dosage* Female Gemfibrozil / administration & dosage* Humans Hyperlipidemias / drug therapy*, metabolism Indoles / administration & dosage* Lipid Metabolism* Lipoproteins / drug effects, metabolism Male Middle Aged Procetofen / administration & dosage* Retrospective Studies Sex Factors Treatment Outcome Triglycerides / metabolism* |
| Chemical | |
Reg. No./Substance:
|
0/Antilipemic Agents; 0/Drug Combinations; 0/Fatty Acids, Monounsaturated; 0/Indoles; 0/Lipoproteins; 0/Triglycerides; 25812-30-0/Gemfibrozil; 41859-67-0/Bezafibrate; 49562-28-9/Procetofen; 93957-54-1/fluvastatin |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Effect of trapidil on cardiovascular events in patients with coronary artery disease (results from t...
Next Document: QRS duration and prediction of mortality in patients undergoing risk stratification for ventricular ...